The UK has launched its largest prostate cancer screening trial in decades, aiming to find the most effective way to detect the disease early. General practitioners have begun sending invitation letters to men who qualify for the study.
The £42 million Transform trial is funded by Prostate Cancer UK and the National Institute for Health and Care Research. Chief investigator Hashim Ahmed described the start of recruitment as a major step toward safer and more accurate prostate cancer diagnosis. He said the results could help the UK finally introduce a national screening programme.
The trial will recruit men aged 50 to 74. Black men can join from age 45 because their risk of developing and dying from prostate cancer is twice that of white men. People cannot volunteer directly; only those who receive an invitation letter will be able to participate. Prostate Cancer UK strongly encourages eligible men to respond.
Researchers will study whether rapid MRI scans, when combined with the prostate-specific antigen (PSA) blood test, can improve diagnostic accuracy. At present, any man over 50 can request a PSA test, but it often gives unclear or misleading results. It can detect cancers that would never cause harm, while missing aggressive ones.
The trial will also test saliva-based DNA analysis to see if it is more reliable than PSA readings alone.
Matthew Hobbs, director of research at Prostate Cancer UK, said that current testing methods are not good enough. They fail to find many dangerous cancers and can lead to unnecessary treatment. He explained that some men suffer long-term side effects such as incontinence or impotence, even when their cancers did not require treatment.
For many families, early detection could be life-saving. Danny Burkey, a 60-year-old from West Yorkshire, is now terminally ill after his cancer was found only after it had spread to his bones. He believes regular screening from age 50 could have changed his outcome. He said a national screening programme is the “obvious solution” to prevent early deaths, which number around 12,000 a year in the UK.
The launch of the Transform trial comes just one week before the National Screening Committee is expected to decide whether to recommend nationwide prostate cancer screening. The committee previously warned that screening might do more harm than good.
Early results from the trial are expected in about two years. After that, the study may expand to include up to 300,000 men across the UK.
Related topics
Study Finds Type 1 Diabetes Strongly Linked to Higher Bladder Cancer Risk
Men’s Health Strategy Promises Big Changes for Men’s Heart Health
ALYREF Biomarker Offers New Hope for Bladder Cancer Treatment
